Remove Big Data Remove Clinical Research Remove Engineer Remove Trials
article thumbnail

Synthetic control arms in clinical trials: Making it happen

pharmaphorum

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials. Can the combined potential of new AI technologies and real-world patient data hold the key to overcoming the challenges in clinical trial design that have historically led to trial failure?

article thumbnail

June 26, 2023: NIMHD Director Discusses Ways Researchers Can Help Reduce Health Disparities

Rethinking Clinical Trials

Pérez-Stable, MD This year’s annual Steering Committee meeting for the NIH Pragmatic Trials Collaboratory featured health equity as a central topic of discussion. Going forward, there is also tremendous value in capturing more granular data on individuals’ heritage and background.

Research 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Massive Bio Launches Industry’s First NASA-Style, Oncology Clinical Trial Command Center to Disrupt and Accelerate Trial Enrollment, Featuring 72-Hour Instant Enrollment from Time of Patient Identification

The Pharma Data

a leader in precision medicine and artificial intelligence (AI)-enabled patient-centric oncology clinical trial enrollment, announced today it has launched its SYNERGY-AI Oncology Clinical Trial Command Center (OCTCC) with the mission to disrupt and accelerate the clinical trial enrollment process.

article thumbnail

Genmab’s Silver Anniversary: Reflecting on 25 Years of Breakthroughs in Antibody Therapeutics

XTalks

XTALKS CLINICAL EDGE: Issue 2 — Genmab’s Interview Xtalks Clinical Edge is a magazine for clinical research professionals and all who want to be informed about the latest trends and happenings in clinical trials. Celebrating 25 years of innovation is a significant milestone.

article thumbnail

Drug discovery in 2023: Five key predictions

Drug Discovery World

There will be greater emphasis on diversity in clinical trials. A focus on the representation of diverse patient populations in clinical trials will be a very good thing for the industry, but could be challenging. DDW’s Diana Spencer summarises the key trends likely to impact the market in 2023. .

Drugs 52
article thumbnail

The future of AI drug discovery & development in immunology and GPCR research

pharmaphorum

Verily’s Immune Profiler platform is “a discovery engine consisting of proprietary immune profiling lab workflow, growing multi-omic database, and advanced analytical tools”. It also bodes well for improving clinical trial success rates. A notable issue with clinical trials is the homogeneity of the patient database.

article thumbnail

AI, big data and real world evidence – the challenges and opportunities

pharmaphorum

Opportunities are growing for real-world evidence research as the technology matures and a pioneering new partnership between Savana, utilising its AI-driven clinical research methodology, and BREATHE aims to drive innovative research using this new way of working. The benefits of RWE. Patient-friendly studies.

Big Data 135